 |
Allogeneic peripheral blood mononuclear cells incubated ex vivo with 16, 16-dimethyl prostaglandin E2 and dexamethasone |
|---|---|
| Trade Name | |
| Orphan Indication | Treatment in haematopoietic stem cell transplantation |
| EU Market Approval | EU |
| EU Designation Date | 2016-11-18 00:00:00 |
| Sponsor | Fate Therapeutics Ltd |
